MAM
Lowe Lintas wins creative duties of Maruti Suzuki Ertiga
MUMBAI: Lowe Lintas has bagged the creative mandate for Maruti Suzuki‘s soon to be launched multi-purpose vehicle (MPV), Maruti Suzuki Ertiga.
According to the industry sources, the account size is estimated to be around Rs 250 million.
The account win was followed by a multi-agency pitch that saw the participation of three agencies including Denstu India, Publicis Capital and Lowe Lintas.
Maruti Suzuki chief general manager- marketing Shashank Srivastava confirmed the news to Indiantelevision.com.
“There was an evaluation process after which Lowe Lintas was handed over the account. We were looking for agency that has good understanding of market and creative ideas for the brand,” Srivastava said.
The car was showcased at AutoExpo 2012 and is expected to be available by April this year. The price will be announced at the time of its launch.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
